Aktis Oncology (AKTS) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Jade Biosciences is the larger company by market cap ($856.7 million vs $837.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | JBIO |
|---|---|---|
| Share price | $15.06 | $13.47 |
| Market cap | $837.63M | $856.66M |
| 1-day change | -5.93% | -2.11% |
| YTD return | — | -12.70% |
| 1-year return | — | +37.66% |
| 5-year return | — | -97.10% |
| EPS (TTM) | $-1.70 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-127.41M |
| 52-week high | $34.19 | $28.00 |
| 52-week low | $14.72 | $8.36 |
| Distance from 52-week high | -55.95% | -51.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +134.99% | +272.16% |
| Average volume | 361.82K | 899.07K |
| Shares outstanding | 53.75M | 63.60M |
| Employees | 79 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
AKTS vs JBIO FAQ
Which is bigger, Aktis Oncology or Jade Biosciences?
Jade Biosciences (JBIO) is larger, with a market capitalization of $856.66M compared with $837.63M for Aktis Oncology (AKTS).
Are Aktis Oncology and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.